Advancing novel treatments for dry eye and ocular surgery


Kala Pharmaceuticals (NASDAQ: KALA) is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.


Year Invested: 2009
Location: Waltham, Mass.
Visit: www.kalarx.com

Recent News

January 18, 2019
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

January 7, 2019
Kala Pharmaceuticals Announces the Launch of INVELTYS™ and the Hiring of a Specialty Ophthalmology Sales Organization

January 2, 2019
Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner